Literature DB >> 11259410

The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification.

D A Sampson1, M Wang, M J Matunis.   

Abstract

SUMO-1 is an ubiquitin-related protein that is covalently conjugated to a diverse assortment of proteins. The consequences of SUMO-1 modification include the regulation of protein-protein interactions, protein-DNA interactions, and protein subcellular localization. At present, very little is understood about the specific mechanisms that govern the recognition of proteins as substrates for SUMO-1 modification. However, many of the proteins that are modified by SUMO-1 interact directly with the SUMO-1 conjugating enzyme, Ubc9. These interactions suggest that Ubc9 binding may play an important role in substrate recognition as well as in substrate modification. The SUMO-1 consensus sequence (SUMO-1-CS) is a motif of conserved residues surrounding the modified lysine residue of most SUMO-1 substrates. This motif conforms to the sequence "PsiKXE," where Psi is a large hydrophobic residue, K is the lysine to which SUMO-1 is conjugated, X is any amino acid, and E is glutamic acid. In this study, we demonstrate that the SUMO-1-CS is a major determinant of Ubc9 binding and SUMO-1 modification. Mutating residues in the SUMO-1-CS abolishes both Ubc9 binding and substrate modification. These findings have important implications for how SUMO-1 substrates are recognized and for how SUMO-1 is ultimately transferred to specific lysine residues on these substrates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259410     DOI: 10.1074/jbc.M100006200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  219 in total

1.  PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies.

Authors:  S Sachdev; L Bruhn; H Sieber; A Pichler; F Melchior; R Grosschedl
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

Review 2.  Modification with SUMO. A role in transcriptional regulation.

Authors:  Alexis Verger; José Perdomo; Merlin Crossley
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

3.  UBC9 autosumoylation negatively regulates sumoylation of septins in Saccharomyces cerevisiae.

Authors:  Chia-Wen Ho; Hung-Ta Chen; Jaulang Hwang
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

4.  PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases.

Authors:  Noora Kotaja; Ulla Karvonen; Olli A Jänne; Jorma J Palvimo
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

5.  Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex.

Authors:  Hong Zhang; Hisato Saitoh; Michael J Matunis
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

6.  SUMO modification of heterogeneous nuclear ribonucleoproteins.

Authors:  Maria T Vassileva; Michael J Matunis
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

7.  CD2AP regulates SUMOylation of CIN85 in podocytes.

Authors:  Irini Tossidou; Rainer Niedenthal; Malte Klaus; Beina Teng; Kirstin Worthmann; Benjamin L King; Kevin J Peterson; Hermann Haller; Mario Schiffer
Journal:  Mol Cell Biol       Date:  2011-12-27       Impact factor: 4.272

8.  N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies.

Authors:  Prashant Sharma; Rodolfo Murillas; Huafeng Zhang; Michael R Kuehn
Journal:  J Cell Sci       Date:  2010-03-16       Impact factor: 5.285

Review 9.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

Review 10.  Structural and functional insights to ubiquitin-like protein conjugation.

Authors:  Frederick C Streich; Christopher D Lima
Journal:  Annu Rev Biophys       Date:  2014       Impact factor: 12.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.